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I. Introduction 
Unlike most industries, the successes and growth of pharmaceutical companies (pharma 
companies) can often lead to the pharma companies’ own vilification by consumers and health 
care practitioners alike.1 The role of pharma companies serving as ‘Public Enemy Number One’2 
is perpetuated by stigmas associated with the great unknown of drug research and production.3 
This animosity towards these companies also arises from lingering questions the general public 
has when considering the long-term effects of prescription drug use.4 Some patients further fear 
that big pharma is out to get the bottom dollar, or that pharma companies are not worried about 
 
1 See, Stephanie Sutton, Why is the Pharma Industry Public Enemy No. 1? (Dec. 12, 2019, 2:29PM), LINKEDIN, 
 
2 Id. 
3 Id. 
4 See, Luis Villalba, Pharmaceutical companies and medical practitioners or “the beast and the beauty”?, 37 
CLINICS IN DERMATOLOGY 1, 16-20 (2019) (discussing the relationships between pharmaceutical companies, 
physicians, and consumers in digital media platforms). 
https://www.linkedin.com/pulse/why-pharma-industry-public-enemy-1-stephanie-sutton/. 
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misleading consumers into buying the ever-increasing amounts of drugs pumped into the 
market.5 
In general, pharma companies have a problem with their reputations in the United States 
(“U.S.”).6 The U.S. is one of only two countries in the world that legally allows pharmaceutical 
companies to advertise directly to consumers through the use of direct-to-consumer 
advertisements (“DTC ads”).7 While patient-consumers are inundated with a wave of different 
drug advertisements each day, it is possible that consumers can forget who and what is behind all 
these ads. Pharma companies invest time, money, and resources in their research, development, 
manufacturing, marketing, advertising, and selling of drugs.8  
All of these investments can be viewed as a means to support and maintain an interest 
many pharma companies have – equalizing and bettering public health.9  While this is not the 
only goal of pharma companies when they make the necessary investments to create and launch 
drugs into the market; indeed, it is still one that links pharma companies’ interests with 
considering the greater public health.10 DTC ads are pivotal to the promotional successes of 
 
5 See, Sarah Van den Bogaert, et al., In the land of pharma: A qualitative analysis of the reputational discourse of 
the pharmaceutical industry, 7 SAGE J. 2, 127-47 (2018) (discussing Bad Pharma discourse and unrealistic standards 
society has set forth for pharmaceutical companies).  
6 Id. 
7 See, ProCon.org, Should Prescription Drugs Be Advertised Directly to Consumers?, (Dec. 12, 2019, 3:03PM), 
PROCON.ORG, [https://prescriptiondrugs.procon.org/]. 
8 See, Sarah Van den Bogaert, et al., In the land of pharma: A qualitative analysis of the reputational discourse of 
the pharmaceutical industry, 7 SAGE J. 2, 127-47 (2018). 
9 See, C. Lee Ventola, Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?, 36 P.T. 10, 669-74, 
681-84 (2011) (discussing direct-to-consumer advertising, regulatory requirements, and the difficulty of enforcing 
these ads in the media by the FDA). 
10 Id. 
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pharmaceuticals.11 Unfortunately, the hazards of misrepresenting public safety and health risks in 
these short bursts of audial/visual persuasion continues to put DTC ads in the hot seat.12 
DTC ads for pharmaceuticals are not only valuable to the success of pharma companies 
but they are also key in the empowerment of consumer-patients.13 DTC ads have increased 
conversations between physicians and patients, and normalized inquiries about ailments and 
diseases that would otherwise go unnoticed or undiscussed between physicians and patients.14 
Furthermore, due to an extensive history of legislation, regulation, and case law, the commercial 
speech of DTC ads is locked down in U.S. history books indefinitely as protected commercial 
speech under the First Amendment (so long as it is truthful and non-misleading).15 This article 
seeks to look at historical attempts to regulate DTC ads in efforts to determine whether 
regulatory agencies and guidelines can reduce the negative effects of DTC ads, while still 
enjoying the ads’ benefits. 
II. What is Direct-to-Consumer (“DTC”) Advertising and How is it Related to Public 
Health? 
DTC ads are a powerful tool and method of communication used by pharmaceutical 
companies to broadcast prescription drug information (including the major statement, risks 
associated, any boxed warnings, counterindications, and other vital information) via different 
media outlets (such as radio, television, or the Internet).16 These ads are a key resource aiding in 
 
11 See, Zaheer-Ud-Din Babar, et al., A review of DTCA techniques: Appraising their success and potential impact on 
medication users, 14 R.S.A.P. 3, 218-27 (2018) (discussing a search and survey of seven electronic databases that 
found DTC ads to be beneficial to the DTC promotion of a drug). 
12 See, Elizabeth A. Almasi, et al., What are the Public Health Effects of Direct-to-Consumer Drug Advertising?, 
PLoS Med. (2006). 
13 C. Lee Ventola, 36 P.T. 10, 669-74, 681-84 (2011). 
14 Id. 
15 Id. 
16 See, Michael S. Wilkes, et al., Direct-To-Consumer Prescription Drug Advertising: Trends, Impact, And 
Implications, 19 HEALTH AFFAIRS 2, (2000) (discussing the impact of direct-to-consumer advertising on consumers 
historically and how drug producers have benefited from them). 
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the success of pharma drug campaigns, as prescription drug information is shared directly to 
consumers to promote and educate patients on alternative treatments and drug options.17 These 
ad campaigns are often exceedingly expensive for pharma companies, and require marketing and 
advertising personnel, as well as legal advisors to ensure compliance with FDA regulatory 
standards.18  
Due to unclear and contradicting standards from the FDA, pharma companies often must 
fill in the gaps in DTC ad development.19 As standards can be confusing, it comes as no surprise 
that DTC ads can frequently lead to misunderstanding for consumers who struggle to digest and 
comprehend the material transmitted through these ads.20 From the pharma perspective, DTC ad 
production requires a great amount of time and effort that is often filled with pressures to 
successfully release an ad campaign that passes muster for both regulating agencies and public 
opinion alike.21 Unlike general product advertisements, DTC ads demand the utmost care and 
management, as the product at hand can have potentially detrimental consequences to society: a 
drug impacting public health and safety.22  
Public health is often defined as “the science and art of preventing disease, prolonging 
life, and promoting physical health and efficiency through organized efforts of society.”23 It is 
 
17 See, Michael S. Wilkes, et al., Direct-To-Consumer Prescription Drug Advertising: Trends, Impact, And 
Implications, 19 HEALTH AFFAIRS 2, (2000). 
18 See, Lisa M. Schwartz and Steven Woloshin, Medical Marketing in the United States, 1997-2016, 321 J.A.M.A 1, 
80-96 (2019) (discussing the analysis that from 1997 through 2016, spending on medical marketing of drugs, disease 
awareness campaigns, health services, and laboratory testing increased from $17.7 to $29.9 billion. The most rapid 
increase was in direct-to-consumer (DTC) advertising, which increased from $2.1 billion (11.9%) of total spending 
in 1997 to $9.6 billion (32.0%) of total spending in 2016. Further explains some of the reasoning behind costs). 
19See, Sarah Van den Bogaert, et al., In the land of pharma: A qualitative analysis of the reputational discourse of 
the pharmaceutical industry, 7 SAGE J. 2, 127-47 (2018). 
20 See, C. Lee Ventola, Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?, 36 P.T. 10, 669-74, 
681-84 (2011). 
21 See, Sarah Van den Bogaert, et al., In the land of pharma: A qualitative analysis of the reputational discourse of 
the pharmaceutical industry, 7 SAGE J. 2, 127-47 (2018). 
22 Id. 
23 WENDY K. MARINER, ET AL., PUBLIC HEALTH LAW 17 (3rd ed. 2019). 
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true that the end goal of pharma companies’ is often to sell their product(s) on the market, and 
utilize DTC ads to increase sales.24 However, with these ads and sales comes a greater 
interaction between pharma companies and consumers that can lead to a change in the public 
health of the nation. This change and development must be observed and regulated. Placing the 
onus of mitigating the negative effects of DTC ads on pharma companies can be far too great a 
burden for a single industry to do on its own. It is also important to note that when consumers 
purchase drugs and increase the profits of pharma companies it can lead to a greater amount of 
funding that can go into continued research and development of alternative treatments and drugs. 
What is unique about DTC ads, their regulations, and the impacts they have on public 
health is the time sensitive nature of the development of ads as well as the regulations.25 With 
each moment of time that passes, a facet of a disease or disorder is developing and morphing.26 
New drugs are being researched, tested, manufactured, and released onto the market. Messages 
and ideas are being shared to a broad audience that carry varied intentions and meanings 
pertaining to pharmaceuticals and their uses. The conditions for creating and enforcing 
regulations in this field are so adaptable and volatile, that it can seem as if law and regulations 
are two steps behind the progress of medicine, working to catch up with the constant evolution 
and innovation. All these factors amount to a high-stake, high-stress environment of working to 
balance the public health and safety risks and benefits in regulations, while allowing pharma 
companies to successfully sell and create more products. 
 
24 See, Lisa M. Schwartz and Steven Woloshin, Medical Marketing in the United States, 1997-2016, 321 J.A.M.A 1, 
80-96 (2019). 
25 See, Richard G. Frank and Paul B. Ginsburg, Pharmaceutical Industry Profits And Research And Development 
(Dec. 12, 2019, 4:12PM), HEALTH AFFAIRS BLOG, 
[https://www.healthaffairs.org/do/10.1377/hblog20171113.880918/full/]. 
26 Id. 
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How DTC ads are viewed and interpreted can vary based on individual experiences, and 
ultimately raises the public health concern of what role these ads play in “inform[ing], 
educat[ing], and empower[ing] people about health issues” to the community at large.27 
Admittedly, consumer comprehension of these drugs’ risks and benefits can be impacted by 
pharma companies’ own efforts to downplay risk or oversell benefits.28 At the same time, 
pharma companies can struggle with meeting FDA guidelines for simple language in their ads to 
limit consumer confusion, which can also lead to obfuscating the risks and benefits of the 
drug(s).29 The tangled webs and balancing act of satisfying both the FDA and the consumer can 
appear next to impossible to navigate for pharma companies.  
The benefits of DTC ads are not just for the pharma company. DTC ads lead to the direct 
targeting of patient-consumers, which has increased the dialogue between patients and their 
physicians.30 Patients are empowered to seek medical advice from physicians pertaining to 
diseases and ailments that have been brought to their attention by these DTC ads.31 Patients feel 
more equipped and more confident to reach out to their physician and speak about diseases and 
disorders that they were either previously unknowledgeable about, or too afraid/insecure to bring 
forward to the table.32 Viewing the symptoms of a disorder on a DTC ad can also normalize and 
decrease the stigmas associated with diseases and disorders, especially ‘invisible disabilities’ 
 
27 WENDY K. MARINER, ET AL., PUBLIC HEALTH LAW 22 (3rd ed. 2019). 
28 See, Niro Sivanathan and Hemant Kakkar, Pharmaceutical Industry Profits And Research And Development (Dec. 
12, 2019, 4:33PM), SCIENTIFIC AMERICAN, [https://www.scientificamerican.com/article/how-drug-company-ads-
downplay-risks/]. 
29 See, C. Lee Ventola, Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?, 36 P.T. 10, 669-74, 
681-84 (2011). 
30 See, ProCon.org, Should Prescription Drugs Be Advertised Directly to Consumers?, (Dec. 12, 2019, 4:53PM), 
PROCON.ORG, https://prescriptiondrugs.procon.org/. 
31 See, ProCon.org, Should Prescription Drugs Be Advertised Directly to Consumers?, (Dec. 12, 2019, 4:58PM), 
PROCON.ORG, [https://prescriptiondrugs.procon.org/]. 
32 Id. 
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regarding mental health.33 This can ease the stress that patient-physician conversations could 
generate for individuals seeking medical help. 
Normalizing these discussions is also particularly helpful in achieving the public health 
interest of equalizing health treatment and access to patients of different socioeconomic 
backgrounds.34 Indeed, “patients with lower incomes and education levels who are less likely to 
seek medical care, in general, were more likely to see a doctor after seeing DTC prescription 
drug ads.”35 This increased dialogue also suggests that patients are more informed about 
diseases/conditions and possible or alternative medical treatments.36 In fact, 48% of doctors 
agree that DTC ads "inform, educate, and empower" patients, as established in an FDA survey.37 
DTC ads also serve as reminders to patients to stay on track of medication/treatment plans as 
well as seek out alternative treatment methods that they might not otherwise have known about.38 
This is extremely beneficial in achieving a public health goal of increasing the quality of care 
and quality of health of the general population.39  
Unfortunately, positive effects can also bring negatives ones as well, and that is certainly 
the case for DTC ads. For one, DTC ads can lead to misinformed patients.40 DTC ads serve as a 
double-edged sword by providing consumers with a wide breadth of new and valuable 
information about pharmaceutical products.41 All the while, this influx of data (often riddled with 
 
33 Id. 
34 Id. 
35 Id. 
36 Id. 
37 Taylor Tyler, Direct-to-Consumer Drug Ads Should Be Scaled Back, Doctors Say, (Dec. 12, 2019, 5:03PM), 
INDEPENDENT VOTER NEWS, [https://ivn.us/2013/06/03/direct-to-consumer-drug-ads-should-be-scaled-back-doctors-
say]. 
38 See, ProCon.org, Should Prescription Drugs Be Advertised Directly to Consumers?, (Dec. 12, 2019, 5:05PM), 
PROCON.ORG, [https://prescriptiondrugs.procon.org/]. 
39 WENDY K. MARINER, ET AL., PUBLIC HEALTH LAW 22 (3rd ed. 2019). 
40 See, ProCon.org, Should Prescription Drugs Be Advertised Directly to Consumers?, (Dec. 12, 2019, 6:05PM), 
PROCON.ORG, [https://prescriptiondrugs.procon.org/]. 
41 See, C. Lee Ventola, Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?, 36 P.T. 10, 669-74, 
681-84 (2011). 
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necessary but complicated medical and legal jargon) can increase the chances that this 
information can also be misinterpreted or misunderstood.42 Despite FDA efforts to regulate the 
vocabulary and verbiage used in these advertisements, the brief duration of the advertisements, 
coupled with often flashy and distracting storylines, can divert the consumer and detract from 
information comprehension and retention.43  The general population does not take the time to 
assess the accuracy and representation of facts shared in pharmaceutical ads, and is likely to be 
susceptible to misunderstanding and misinterpretation of the risks that are associated with the 
drugs seen on the ads.44 This reality increases the risk of misleading and deceptive information 
being shared with all consumers – both informed and uninformed. 
Additionally, long-term health and safety risks of prescription drugs are often not 
determined upon the release of DTC ad campaigns.45 This can lead to a misunderstanding of the 
current and future harms and counterindications that could arise in the consumption of the 
advertised drugs.46 In 2011, a survey found that 43% of patients believed drugs advertised on 
DTC ads were 100% safe when being marketed.47 This suggests that portions of the general 
population have misinterpreted the risks of the drug advertised, and could be placing their health 
at risk because of this misguided trust in what consumers hear and see in DTC ads.48  
Another concern is raised that the popularization of DTC ads results in the over-filling 
and over-consumption of prescription drugs.49 This concern has been raised for attention deficit 
 
42 Id. 
43 Id. 
44 See, ProCon.org, Should Prescription Drugs Be Advertised Directly to Consumers?, (Dec. 12, 2019, 6:10PM), 
PROCON.ORG, [https://prescriptiondrugs.procon.org/]. 
45 Id. 
46 Id. 
47 Id. 
48 Id. 
49 See, ProCon.org, Should Prescription Drugs Be Advertised Directly to Consumers?, (Dec. 12, 2019, 6:15PM), 
PROCON.ORG, [https://prescriptiondrugs.procon.org/]. 
8
Health Law Outlook, Vol. 11 [2020], Iss. 1, Art. 1
https://scholarship.shu.edu/health-law-outlook/vol11/iss1/1
hyperactivity disorder (ADHD).50 In 2014, ADHD medication prescriptions were written 
approximately 25 times more frequently in the United States than in the United Kingdom (where 
DTC ads are not allowed), and this number keeps rising.51 This one example reflects the growing 
concern in the public health field that there could be an increase in the usage of prescription 
medication correlated to the increase in patient-physician conversations about these drugs.  
While some experts argue that the dramatic rise in prescription filling is clear evidence 
that the ADHD indication is being diagnosed and medically treated (for children, in particular) 
far surpassing reasonable rates, proponents of DTC ads argue otherwise.52 These individuals 
argue that the risk of overfilling prescriptions is outweighed by the triumphs of prevention, early 
detection, mitigation, and treatment of illnesses and disorders.53 Proponents argue that DTC ads 
have normalized symptoms of ADHD and have empowered children and adults to approach 
physicians and seek pharmaceutical drug assistance with these ailments.54 In the end, DTC ads 
for ADHD drugs and other pharmaceuticals must fight to balance the public health and safety 
risks and benefits, and how to best share that information with the public. 
III. FDA guidelines and regulation  
Since the information shared through DTC ads implicates the general public health, this 
information is regulated in a somewhat similar fashion as public health programs would be 
regulated. Public health programs are influenced, if not generally controlled, by a federal 
 
50 See, Alan Schwarz, Report Says Medication Use Is Rising for Adults with Attention Disorder, (Dec. 13, 2018, 
7:22PM), NYTIMES, [https://www.nytimes.com/2014/03/12/us/report-says-medication-use-is-rising-for-adults-with-
attention-disorder.html/]. 
51 See, Alan Schwarz, Report Says Medication Use Is Rising for Adults with Attention Disorder, (Dec. 13, 2018, 
7:22PM), NYTIMES. 
52 Id. 
53 See, Steven Woloshin, et al., The Value Of Benefit Data In Direct-To-Consumer Drug Ads, HEALTH AFFAIRS, 
(Dec. 13, 2019 7:26PM), [https://www.healthaffairs.org/doi/full/10.1377/hlthaff.W4.234]. 
54 See, Alan Schwarz, Report Says Medication Use Is Rising for Adults with Attention Disorder, (Dec. 13, 2019, 
7:29PM), NYTIMES. 
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government agency.55 In this case, the Food and Drug Administration (“FDA”) is the leading 
government agency that regulates DTC ads pursuant to the Food, Drugs & Cosmetics Act 
(“FDCA”).56 It is the FDA’s responsibility to oversee advertising for prescription drugs (to note, 
this is not applicable for over-the-counter medication).57 Furthermore, the FDA’s Office of 
Prescription Drug Promotion (“OPDP”) is the subsection of the FDA that reviews and provides 
advisory comments (oftentimes, in the form of either Untitled or Warning enforcement letters) 
regarding these pharmaceutical DTC ads.58   
In efforts to hold pharmaceutical companies accountable, the FDA has set forth standards 
for what drug ads must tell consumers.59 DTC ads are required to: “(1) Not be false or 
misleading; (2) Present a fair balance of risk and benefit information; (3) Include facts that are 
material to the product’s advertised uses; and (4) Include a brief summary of every risk described 
in the product’s labeling.”60 This can be done by requiring drugs ads to express to consumers 
three key things: “(1) at least one approved use for the drug; (2) the generic name of the drug; (3) 
and all the risks of using the drug (or under certain circumstances, only the most important).”   
Though these standards and criteria can be useful in mitigating some of the negative 
consequences of DTC ads, scholars argue that retrospective review of these ads can be injurious 
to the consumers and pharma alike.61 Consumers, empowered by what they view in DTC ads, are 
often persuaded by the images and storyline that provide hopes for a ‘cure-all’ or at least a 
 
55 WENDY K. MARINER, ET AL., PUBLIC HEALTH LAW 11 (3rd ed. 2019). 
56 See, Food and Drug Administration, Prescription Drug Advertising: Questions and Answers, (Dec. 13, 2019 
7:36PM), FDA.GOV, [https://www.fda.gov/drugs/prescription-drug-advertising/prescription-drug-advertising-
questions-and-answers]. 
57 See, Food and Drug Administration, Prescription Drug Advertising: Questions and Answers, (Dec. 13, 2019 
7:36PM), FDA.GOV. 
58 Id. 
59 Id. 
60 Id. 
61 See, Rachel Groman, Direct-to-Consumer Prescription Drug Advertising, AMERICAN COLLEGE OF PHYSICIANS, 12 
(2006). 
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potential solution to the ailments they are facing. Patients are often eager to reach out to their 
physicians about a new treatment, rather than wait for a period of time in hopes that the FDA has 
gotten around to reviewing and assessing these ads for any misleading information presented. If 
OPDP was to review DTC ads prior to their initial release, it could circumvent much of the 
confusing conversations that are held between physicians and patients. 
In the meantime, pharma companies make great investments in DTC ad campaigns, and 
often feel it necessary to release these ads as soon as possible to have their product gain traction 
and sell in the market.62 A delay in the release of an ad campaign could be detrimental to the 
success of the product launch and lead to financial struggles for the company. The costs incurred 
can escalate even more when the FDA then issues an enforcement letter demanding the company 
take down these expensive ad campaigns and release new ones.63 The requirement to apologize 
and clarify for mistakes made by the company in the initial DTC ad campaigns in a later ad 
campaign can also cost the pharma company credibility and reputation points.64 This is 
especially detrimental where pharmaceutical companies already struggle with maintaining 
positive reputations and credibility in the eye of the consumers.65  
All of these costs incurred by pharma companies implies that they are unlikely to want to 
continuously recreate drug ads repeatedly. It is in both to the pharma companies’ and the 
consumers’ benefit to work with FDA regulations and guidelines to prepare and disseminate 
meaningful and truthful advertisements the first time around. Unfortunately, the history of DTC 
ads regulations and guidelines has been as complicated, if not more, than it is now. 
 
62 See, Rachel Groman, Direct-to-Consumer Prescription Drug Advertising, AMERICAN COLLEGE OF PHYSICIANS, 7 
(2006). 
63 See, The FDA Group, 5 Indirect Costs of an FDA Warning Letter, (Dec. 13, 2019 7:51PM), THEFDAGROUP.COM, 
[https://www.thefdagroup.com/blog/2016/02/5-indirect-costs-of-an-fda-warning-letter/]. 
64 Id. 
65 Id. 
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IV. A Look at Pharmaceutical Advertising Regulations Over Time 
It is critical to look at the history of pharma advertising to identify patterns and efforts 
that can be used presently to reduce the negative effects DTC ads may have. The start of federal 
DTC drug regulations can be seen in the Progressive Era, as a means to regulate the few ‘ethical’ 
and ‘on the book’ drugs that were then on the market.66 At this time, the 1906 Pure Food and 
Drug Act67 applied, as it prohibited interstate transport of unlawful drugs.68 Elements reminiscent 
of portions of this statute will continue and evolve into modern regulations to date.  
The Pure Food and Drug Act is rooted in protections of proper (or rather, inappropriate) 
labeling on food and drugs.69 While modern FDA regulations often relates to premarket approval 
and uses, recently there has been a shift of concern once again towards labeling (e.g., off-label 
uses of pharmaceuticals).70 The Pure Food and Drug Act also required that “no detail of a drug 
label could be false or misleading and even required labels to list the existence and/or 
concentration of eleven different ‘dangerous substances’.71 Some controversy arose early on 
regarding the reliability of therapeutic claims of drugs, as U.S. v. Johnson ruled that it was not 
prohibited to falsely advertise therapeutic claims.72 Ultimately, in a showing of the push and pull 
between the Court and Congress, the Shirley Amendment overruled Johnson by prohibiting 
 
66 See, Julie Donohue, A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, 
84 PMC 4, 659-99 (2006). 
67 Id. 
68 Id.  
69 34 Stat. at L. 768. 
70 See, Julie Donohue, A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, 
84 PMC 4, 659-99 (2006). 
71 34 Stat. at L. 768. 
72 U.S. v. Johnson, 952 F.2d 565 (1st Cir. 1991). 
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claims that could ‘defraud the purchaser’.73 This debate continues into modern day concerns of 
how to best avoid having DTC ads misrepresent the risks and benefits of a drug.74 
In 1938, the FDCA was passed as a statutory recognition that consumers, who were 
generally self-medicating at the time, brought about public health concerns in their use of 
pharmaceuticals without the presence of further federal regulations.75 While the FDA had 
recognized over twenty dangerous substances that could not be obtained over-the-counter 
(“OTC”) or without prescription, it had become apparent that patients obtaining pharmaceuticals 
were at risk. In turn, the FDCA worked to expand the FDA’s authority in drug regulation and 
mandated, for the first time, that drugs be proven safe for consumers by obtaining approval 
before being marketed.76 FDCA also continued to expand FDA drug labeling requirements to 
include more than the name and ingredients of the drug.77 The initial FDCA labeling 
requirements can be likened to labels consumers see today in OTC drug labels.78 Unfortunately, 
the FDA’s effectiveness in regulating through the FDCA was greatly limited by the passage of 
the Wheeler Lea Act in 193879, which granted jurisdiction and authority of drug advertising to 
the Federal Trade Commission (“FTC”).80 
Historically, pharmaceutical companies could only advertise their products to 
physicians.81 This prevented direct communication and education to the patients, who were left 
 
73 See, Julie Donohue, A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, 
84 PMC 4, 659-99 (2006). 
74 Id. 
75 Id. 
76 Id. 
77 Id. 
78 Id. 
79 15 U.S.C.S. § 45(l). 
80 See, Julie Donohue, A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, 
84 PMC 4, 659-99 (2006). 
81 See, ProCon.org, History of Prescription Drug Ads (Dec. 13, 2019, 7:50PM), PROCON.ORG, 
[https://prescriptiondrugs.procon.org/history-of-prescription-drug-ads/]. 
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underinformed of potential diagnoses and treatments to the ailments they were facing.82 This also 
made diversifying the pool of consumers and broadening the base of patients limited at the start 
of pharmaceutical development.83 Now, with a broader pool of consumers, there is the chance of 
increased understanding in the uses and effects of prescription drug consumption, if and when 
post-marketing research is conducted. With a larger pool of consumers, research findings could 
be considered more inclusive and more in-depth. 
Additionally, the unclear distinction between OTC and prescription drugs in regulations 
led to general confusion and varied uses of drugs prescribed by the physicians.84 It was with the 
passage of the Durham Humphreys Amendments (“DHAs”) to the FDCA that a statutory 
definition of prescription drugs was finally passed and could lend itself to better regulations of 
the drugs in the future.85 However, the DHAs backfired in that pharmaceuticals classified as 
prescription drugs soon saw less of the full product labeling required of OTC drugs.86 The 
struggle to regulate what safety risks and drug information was being shared to consumers has, 
and always will be, a battle for pharma companies and the FDA as a regulatory agency. 
A. Federal Policy on Pharmaceutical Marketing in the 1960s and Beyond 
Ultimately, the involvement and regulation of the FDA in DTC ads is one of the reasons 
these ads have become so omnipresent in the American market system.87 The FDA garnered its 
expansive authority in advertising regulations in 1969, when it passed a regulation requiring 
advertisements contain a “true statement of information in brief summary relating to side effects, 
 
82 Id. 
83 See, The FDA Group, 5 Indirect Costs of an FDA Warning Letter, (Dec. 13, 2019 7:51PM), THEFDAGROUP.COM, 
[https://www.thefdagroup.com/blog/2016/02/5-indirect-costs-of-an-fda-warning-letter/]. 
84 See, Julie Donohue, A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, 
84 PMC 4, 659-99 (2006). 
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contraindications, and effectiveness” (FDA/DHHS 1969)88. Additionally, DTC ads must present 
a “fair balance” between information presented about the drug's side effects and 
contraindications and the drug’s effectiveness.89 The regulations even go so far as to explain to 
consumers and pharma companies how an advertisement could be considered false, unbalanced, 
or otherwise misleading.90 
The FDA’s authority in regulating pharma drugs is one of the agency’s primary means in 
meeting a main goal the FDA has in safeguarding public health and safety in the use of 
pharmaceuticals.91 This interest, coupled with the growing Patient’s Rights Movement in the 
1970s (whose goal was to require physicians to provide patients with alternative treatment plans) 
launched the wave of pharma advertising that is regulated in part by the consideration of the 
overall public health and well-being.92  
B. First Amendment Protections 
DTC ads are here to stay in the American market system, with both their pros and cons, 
largely because these ads can be considered protected speech under the First Amendment.93 The 
First Amendment is implicated in the use of DTC ads, as the FDA seeks to regulate meaningful 
and truthful information pharma companies share within these ads, in hopes to limit the negative 
public health effects these ads can have.94  With DTC ads right at the fingertips of consumers, 
concerns about mass sharing of complicated and risky medical information compete against First 
 
88 Id. 
89 Id. 
90 See, Julie Donohue, A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, 
84 PMC 4, 659-99 (2006). 
91 Id. 
92 Id. 
93 See, ProCon.org, Should Prescription Drugs Be Advertised Directly to Consumers?, (Dec. 13, 2019, 8:15PM), 
PROCON.ORG, [https://prescriptiondrugs.procon.org/]. 
94 See, Julie Donohue, A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, 
84 PMC 4, 659-99 (2006). 
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Amendment guarantees and protections of freedom of speech (advertisements as forms of 
commercial speech).95  
First Amendment protections extend to commercial speech, or speech related to the 
economic interests of the speaker and its audience.96 A complete ban of commercial speech not 
only injures the commercial interests of the producer of speech, but also that of the consumers 
who have a societal interest in obtaining the fullest amount of information and then choosing 
what they do and do not agree with.97It is not only in the pharma’s interests to advertise their 
drugs, but also in the consumers, who have their best interests in mind, in digesting information 
within advertisements.98 
In considering how DTC ads can now be better regulated to minimize the negative effects 
that they can have on the general public health, it is important to look at how the regulation of 
commercial speech is treated in general. Central Hudson Gas & Elec. Corp. v. Pub. Serv. 
Comm’n of New York sets forth a standard that if commercial speech is “neither misleading nor 
related to unlawful activity”, government and agency’s regulatory authority is limited.99 If the 
State then asserts a substantial interest in restricting this commercial speech, the method of 
regulation must then be in proportion to that interest, specifically designed to meet that particular 
State goal.100 A framework of these criteria is as follows: “(1) the restriction must directly 
advance the State interest involved; the regulation may not be sustained if it provides only 
ineffective or remote support for the government's purpose; and (2) if the governmental interest 
 
95 Id. 
96 See, Virginia State Bd. of Pharmacy v. Virginia Citizens Consumer Council, Inc., 425 U.S. 748, 748 (1976). 
97 See, Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm'n of New York, 447 U.S. 557, 561–62 (1980). 
98 See, Central Hudson, 447 U.S. 557, 561–62 (1980).  
99 See, 447 U.S. 557, 564 (1980). 
100 Id. 
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could be served as well by a more limited restriction on commercial speech, the excessive 
restrictions cannot survive”.101 
While Central Hudson is an electrical utilities company that brought suit against the NY 
Public Service Commissioner for regulations that wholly banned promotional electrical 
advertising, the concept against banning commercial speech has also extended its application to 
include DTC ads.102 A brief outline of Central Hudson framework from above for application in 
future considerations of commercial speech is as follows: whether,  
“(1) the expression is protected by the First Amendment. For commercial speech 
to come within that provision, it at least must concern lawful activity and not  
be misleading; (2) the asserted governmental interest is substantial; and if both 
inquiries yield positive answers, (3) the regulation directly advances the  
governmental interest asserted, and (4) it is not more extensive than is necessary 
to serve that interest.”103 
In Thompson v. Western States Medical Center,104 the Supreme Court applied the Central 
Hudson105 framework in determining whether FDA regulations on compounded drug advertising 
was a violation of First Amendment protections.106 Thompson notes that it is the burden of the 
party wishing to uphold the restriction on the commercial speech to justify such a restriction.107 
Thompson stands out as a valuable case for future DTC ad regulations, as the court explicitly 
states that hypothesized justifications for State’s interests are not sufficient to impose heightened 
 
101 Id. 
102 Id. 
103 See, 447 U.S. 557, 566 (1980). 
104 See, Thompson v. W. States Med. Ctr., 535 U.S. 357 (2002). 
105 See, Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Commn., 447 U.S. 557 (1980). 
106See, Thompson v. W. States Med. Ctr., 535 U.S. 357 (2002). 
107 535 U.S. 357, 373 (2002). 
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restrictions on commercial speech, unless used on a rational basis review.108 The Central Hudson 
standard of review for commercial speech is stricter than rational basis.109 In the case of 
Thompson, the court notes that even if the fear that these advertisements would motivate patients 
(even those who did not need to risk being exposed to the consumption of unneeded drugs) to 
convince their physicians to prescribe these drugs, it still fails as justification for narrow 
restriction of advertising as commercial speech.110  
This concern of overprescribing without a founded need is one that is still raised amongst 
consumers and physicians observing the trends of increased prescription writing and filling 
today.111 It can be argued that there is an increased public health and safety risk generated from 
the rise in patients seeking prescriptions for drugs that they might not otherwise have needed or 
wanted prior to viewing a DTC ad.112 However, proponents of stricter monitoring and regulation 
of DTC ads must show that any such interest argued must first surpass that which is found 
insufficient here in Thompson, which can be challenging.113  
i. First Amendment Application to Off-Label Use Advertisements 
Pharma companies are generally prohibited from marketing and advertising off-label uses 
(uses of drugs not authorized or recognized within the indications and uses of the formal FDA-
approved label).114 Therefore, an off-label use of a drug is any use in which has not been 
authorized by the FDA. While pharma companies can try to be cautious in any advertising of off-
 
108 Id. 
109 Id. 
110 Id. 
111 See, Robert H. Shmerling, Harvard Health Ad Watch: What you should know about direct-to-consumer ads, 
(Dec. 13, 2019, 8:18PM), HARVARD HEALTH BLOG, [https://www.health.harvard.edu/blog/harvard-health-ad-watch-
what-you-should-know-about-direct-to-consumer-ads-2019092017848]. 
112 Id. 
113 See, 535 U.S. at 360. 
114 See, Elizabeth Richardson, Off-Label Drug Promotion, (Dec. 12, 2019 8:20PM), HEALTH AFFAIRS, 
[https://www.healthaffairs.org/do/10.1377/hpb20160630.920075/full/]. 
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label uses, in fear of repercussions faced by FDA enforcement, it is quite common and very legal 
for physicians to prescribe these drugs for off-label uses.115 In fact, “an estimated one in five 
prescriptions filled” are for the purposes of off-label uses of prescription drugs.116 Prescribing 
off-label is not as peculiar as it may sound; in fact, many times uses of pharmaceuticals are 
identified after a drug has underwent FDA approval and label authorization.117  
Still, off-label prescribing is not clinically ethical, as the side effects and general 
implications of off-label uses have not been extensively studied in FDA-approved studies like 
on-label uses have.118 Off label-uses and unintentional advertisements can also expose pharma 
companies to legal problems.119 For example, in 2012, GlaxoSmithKline (“GSK”) was fined $3 
billion by the federal government, partially due to off-label promotion of several of its drugs.120 
This can be particularly challenging for pharma companies that wish to inform consumers and 
physicians alike of the potential risks and benefits of off-label uses, especially noting that 
physicians legally can, and often, do prescribe medication for off-label uses.121 
In Sorrell v. IMS Health122, the Supreme Court ruled a state statute prohibiting the sale, 
disclosure, or use of physician prescribing records for the purpose of marketing violated the First 
Amendment.123 The court found that the restrictions did not advance a substantial government 
interest and that the statute placed an undue burden on commercial speech.124 This line of case 
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116 Id. 
117 Id. 
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120 See, Elizabeth Richardson, Off-Label Drug Promotion, (Dec. 12, 2019 8:20PM), HEALTH AFFAIRS, 
[https://www.healthaffairs.org/do/10.1377/hpb20160630.920075/full/]. 
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122 See, Sorrell v. IMS Health Inc., 564 U.S. 552 (2011). 
123 See, 564 U.S. 552, 567-68 (2011). 
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law continues with United States v. Caronia.125 In Caronia, the defendant appealed a conviction 
where he is found “guilty of conspiracy to introduce a misbranded drug into interstate 
commerce… [by promoting] the drug…for ‘off-label use’…for a purpose not approved by 
the…FDA.”126 Defendant Coronia argued the conviction violated his First Amendment freedom 
of speech protection, and the Supreme Court agreed.127 The FDCA prohibits misbranding of a 
drug (e.g., product labeling fails to bear “adequate directions for use”).128 This prohibition not 
only extends to DTC ads, but, as Caronia shows, representations of off-label uses of drugs as 
well. 
In Amarin Pharma Inc. v. United States FDA, the court shows a great interest in 
promoting the sharing of truthful, non-misleading information, free from the threat of 
misbranding charges against the pharmaceutical company by federal regulatory agencies (i.e. the 
FDA).129 This interest is similar to that found in the use of DTC ads. Pharma companies 
advertise to the general public alternative treatment methods via DTC ads.130 The naturally 
restrictive nature of timed DTC ads, combined with the complex subject matter, can render the 
danger of misleading risk information a concern, no matter how many restrictions and 
regulations are put in place. In the end, the court tends to favor the least restrictive manner of 
regulating commercial speech, as applied here.131 In attempts to mitigate the negative effects of 
DTC ads, it is important to assess and determine how restrictive the effort would be to the 
commercial speech, and if it was ‘more extensive than necessary’.132 
 
125 United States v. Caronia, 703 F.3d 149, 152 (2d Cir. 2012). 
126 Id. 
127 Id. 
128 21 U.S.C. § 352(f). 
129 Amarin Pharma, Inc. v United States FDA, 119 F. Supp. 3d 196, 198 (S.D.N.Y. 2015). 
130 Id. at 198. 
131 Id. at 226. 
132 Id. 
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Hypothetically, if Congress was to pass a law that prohibited pharma companies from 
advertising directly to consumers, then a claim for violation of the First Amendment protection 
of freedom of speech would have to be brought to court. Using the Central Hudson framework, 
legal representation, including attorneys representing pharma companies, would argue first and 
foremost that a DTC ad is an expression protected by the First Amendment. DTC ads contain 
valuable advertising information on new drugs that is intended to inform consumers of 
alternative treatments on the market. The content of DTC ads has been established to be lawful 
activity, and so long as this information is truthful and not misleading by following FDA 
guidelines, the first step of the Central Hudson framework can be considered satisfied. 
The second step would then be to consider if the asserted governmental interest is 
substantial. With support from Thompson, concerns about consumer enthusiasm for new drugs 
that could lead to overprescribing medication is not a justified argument. Such an argument 
belittles the reality that physicians are skilled in their profession as to not be swayed by patient 
persuasion, and at the same time, patients are entitled to speak their minds and interests to 
physicians. Another possible governmental interest, misinterpreting risks of drugs in DTC ads, 
can be considered substantial as it is a public health implication that consumers are not 
comprehending the extent and degree of risks presented in DTC ads.  
The third and fourth steps would be to consider whether the regulation directly advances 
the governmental interest asserted, and whether such a regulation is not more restrictive than 
necessary to serve that interest. Case law suggests that a total ban on commercial speech violates 
protected First Amendment freedom of speech rights. Even in the event that a regulation was to 
restrict and not totally ban pharma companies from advertising directly to consumers, the Court 
will still refer to commercial speech case law when overruling prohibitions on advertising of 
21
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drugs. For these reasons, it is unlikely that legislative regulations of DTC ads will be successful 
in achieving the desired result of reducing the harmful effects viewing DTC ads can have on 
consumers.  
ii. Counter-advertising 
When it comes to the advertising of products that prove to be a heightened public health 
risk, the tobacco industry and counter-advertising created against its products, shines as an 
example of mitigating health risks. When the FDA recognized the public harm caused by 
tobacco and tobacco-based products, it took measures in passing the Family Smoking Prevention 
and Tobacco Control Act.133 The landmark case of Discount Tobacco City & Lottery, Inc. v. U.S. 
held that under the Central Hudson test, the deceptive nature of tobacco products advertisements 
that deceitfully promoted health claims, outweighed the interest of protected commercial 
speech.134 This can be a case to look at in the future for examples of restricting First Amendment 
protected speech. 
In 2014, the Centers for Disease Control and Prevention (“CDC”) identified smoking and 
the use of tobacco products as a health and safety concern, which encouraged the agency to 
launch and release a national tobacco education campaign.135 A twelve-week campaign had been 
previously released in 2012 but was not nearly as effective because of the manner in which the 
counter-advertisements were presented then.136  The latest method created two phases that 
provided a succession of new and interesting counter-advertisements that educated the public in 
smoking risks and health-related issues.137  Then-CDC Director, Tom Frieden, M.D., M.P.H., 
 
133 21 U.S.C. § 387k(b)(2)(A). 
134 See, Disc. Tobacco City & Lottery, Inc. v. United States, 674 F.3d 509, 533 (6th Cir. 2012). 
135 See, Centers for Disease Control and Prevention, Tips from Former Smokers, (Dec. 13, 2019, 8:38PM), 
CDC.GOV, [https://www.cdc.gov/tobacco/campaign/tips/about/index.html]. 
136 Id. 
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argued the “TIPS” campaign was extremely cost-effective because it saved not only money, but 
also lives.138  In fact, “approximately 17,000 premature deaths from smoking were estimated to 
be averted, and 179,000 years of healthy life gained.”139 
The CDC was one of, if not the only, agency/company that was able to compete with the 
billion-dollar tobacco advertising industry because of its own financial standing, prominence, 
and value.140 The CDC triumphed because the effective and constant release of these informative 
advertisements was difficult for consumers to avoid and easy to recall back into memory when 
consumers were tempted to later reach for that cigarette.  
Comparatively, the pharmaceutical industry and its use of DTC ads plays a different role 
than that of the tobacco companies’ ads. The objective of pharma companies is not to mass-
produce and sell a specific product for the use, enjoyment, and entertainment of the general 
population, regardless of the health implications as tobacco products posed. DTC ads are used as 
a tool to inform consumers of new and innovative products on the market intended to assist and 
aid in diseases and disorders that otherwise hamper the greater level of public health within the 
U.S. population.141 Therefore, the purpose of the products being advertised in the information 
within DTC ads is to aid the public health. The side effects and risks that come with the use of 
these drugs are issues that will arise in continuum as far as advancements of medicine is 
concerned. But to truly identify DTC ads in the same light as tobacco-products, is to completely 
ignore the intents and purposes of medicine and pharmaceutical drugs for the public health as a 
whole. While it is also the goal of pharma companies to obtain profits from selling drugs to 
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141 See, Luis Villalba, Pharmaceutical companies and medical practitioners or “the beast and the beauty”?, 37 
CLINICS IN DERMATOLOGY 1, 16-20 (2019). 
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patients, it is ultimately at the choice of the consumer who must still go to a physician and obtain 
a prescription for these drugs. To note, while both products largely come down to consumer 
choice, ultimately, medications can have both positive and negative effects, while science has 
now deduced that tobacco-based products simply have negative side effects.  
All these elements considered are important to keep in mind when thinking about what 
kind of information and tactics can be utilized in any form of counter-advertising for DTC ads. 
At this time, in reviewing all the effectiveness and success found in the scientific promotion and 
production fostered by the pharmaceutical industry, it is unlikely that the CDC will determine an 
emergent health risk here as it did with the tobacco industry. 
Instead of counter advertising against DTC ads, members of the medical profession 
should be further expected to clarify and assist in comprehension of information in DTC ads for 
the consumers. When it comes to advertising prescription drugs, physicians have notified the 
FDA and CDC in different FDA-approved studies that DTC ads are one of many factors 
influencing how the doctors will practice and interact with patients.142 DTC ads have empowered 
patients to make their own health care decisions and ask far more thoughtful and engaging 
questions with their physicians.143 Furthermore, in these studies, physicians have acknowledged 
a general industry belief that patients understand “they need to consult a health care professional 
about appropriate treatment.”144 With all this considered, it is advisable, and would be greatly 
beneficial, if physicians used their duty of care and trusted physician-patient relationship to take 
on some of the onus of DTC ad clarification. That is, pharma companies are restricted to a short 
 
142 See, Carol Lewis, The Impact of Direct-to-Consumer Advertising, 37-38 FDA CONSUMER 1, 9 (2003). 
143 Id. 
144 Id. 
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period of time and often confusing guidelines in trying to truthfully represent the risks and 
benefits of drugs advertised in DTC ads.  
When a patient engages in inquiries regarding drugs seen on DTC ads, a physician could 
then further explain the potential risks and benefits of the drug in efforts to clarify any 
misunderstandings the patient may have. This can be done in hopes of educating the public 
further and clarifying any misconceptions or misunderstandings from viewing the initial DTC 
ads. While this might be difficult to accomplish, it could be one of the more successful 
alternatives for minimizing the negative effects of DTC ads, without hampering the successes 
pharma companies see in the utilization of DTC ads. 
C. FDA Enforcement Letters 
One struggle the FDA has in supervision and regulation of DTC ads is that the agency 
does not review DTC ads prior to their release and viewing by the general public.145 
Unfortunately, the parameters set forth by the First Amendment guarantee of freedom of speech 
thus far prevents the regulation of information before it has even been disseminated.146 Instead, 
the FDA is forced to act quickly (though that is often difficult due to the high submissions and 
reviews of different DTC ads) and view the streaming ads for any misleading information or 
misrepresentation of risks right alongside the consumers viewing the ads.147 This heightens the 
risk of consumers viewing inappropriate ads for violating standards or providing misleading 
information. The FDA acknowledges similar sentiments found by the Court in Thompson that 
consumers should operate under the impression that not all information has been vetted for the 
 
145 See, U.S. Food and Drug Administration, Types of FDA Enforcement Actions, (Dec. 13, 2019, 8:59PM), 
FDA.GOV, [https://www.fda.gov/animal-veterinary/resources-you/types-fda-enforcement-actions]. 
146 See, The FDA Group, 5 Indirect Costs of an FDA Warning Letter, (Dec. 13, 2019 9:01PM), 
THEFDAGROUP.COM, [https://www.thefdagroup.com/blog/2016/02/5-indirect-costs-of-an-fda-warning-letter/]. 
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absence of misleading or misinforming presentation of risks associated. While the dangers of 
having ads viewed by both the FDA and consumers for the first time simultaneously could 
significantly support altering the rules set forth to allow the FDA to review advertisements 
proactively, it is unlikely to happen given the court precedents.148  
The FDA releases warning letters and letters of notice of violation (otherwise known as 
untitled letters) to pharmaceutical companies when they are in violation of the criteria set forth 
by OPDP.149  When an untitled letter is presented to a pharmaceutical company, the company is 
expected to cease distribution of the misleading or misrepresentative information and proceed 
with sharing amended information to clarify any misunderstandings in new DTC ad 
campaigns.150  Warning letters, as the name suggests, take reprimanding a step further, and 
require the pharma company to issue a letter and/or plan of action to the FDA detailing how the 
company will remediate any potentially deceptive messages they have shared, and any consumer 
mistrust engendered by these ads.151  
Enforcement letters fall short in effectiveness because of an agency requirement where, 
in order to issue a letter and deem speech to be false or misleading in a DTC ad, OPDP must first 
find evidentiary support that the speech is false or misleading.152 This is especially challenging 
given that the quantification of false or misleading information can vary greatly, depending on 
the level of how informed a consumer is when viewing and processing the advertisement. For 
this reason, it seems wise and altogether more productive to create FDA pre-approved language 
templates or a form of guidance that pharma companies can use and abide by when initially 
 
148 See, Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Commn., 447 U.S. 557 (1980). See also, Thompson v. W. 
States Med. Ctr., 535 U.S. 357 (2002). 
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constructing their DTC ad campaigns. If these guidelines and frameworks were then made public 
to be used as pre-sets for DTC ads, it could hopefully provide consistency and avoid 
misrepresentation or confusion in the future.  
Oftentimes, consumers are not even aware that some of the most popular DTC ad 
campaigns are taken down or altered in response to the issuance of an FDA Enforcement 
Letter.153 Requiring pharma companies to notify consumers of any changes made to their DTC 
ad campaigns, pursuant to violations cited by the FDA, can increase the level of awareness and 
understanding for the patient-consumer.  Making note of these changes in newer campaigns on 
top of having pharma companies explaining these changes further in letters released on their 
website and social media could likely better inform consumers that there have been changes 
made to any misleading information previously presented. This is one way to hopefully mitigate 
some of the negative consequences that come with misleading information presented in DTC 
ads, in hopes of also maintaining the pharma company’s credibility and success rate. 
V. Where Do We Go From Here? 
 Pharma companies are not the enemies simply because they seek to make a profit in a 
challenging industry. DTC ads are used to promote new and innovative drugs in hopes of 
appealing to consumers. Exciting messages and catchy music found in all kinds of 
advertisements are also found in DTC ads. However, as has already been discussed, a key 
component to the pharma industry is the necessity of care in presenting the product facts and 
information within these advertisements. While legislation might seem like the best way to 
regulate these ads, any state or federal law passed is likely to struggle against the Central 
 
153 See, Martin T. Gahart, et al., Examining the FDA’s Oversight of Direct-to-Consumer Advertising, (Jun. 12, 2020 
12:25PM), HEALTH AFFAIRS, [https://www.healthaffairs.org/doi/full/10.1377/hlthaff.W3.120]. 
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Hudson framework, which protects First Amendment commercial speech when it is truthful and 
not misleading. 
 Additionally, for the members of the public who are concerned with the risk DTC ads 
may pose in popularizing prescription drugs, and potentially leading to the abuse of these drugs, 
the FDA released a statement on July 1, 2019.154 In this statement, the FDA promises to work 
towards a new goal related to this new topic: Drug Abuse and Dependence Section of Labeling 
for Human Prescription Drug and Biological Products - Content and Format.155 One of the goals 
of this new guidance is to inform consumers about ways to interpret product labels and 
advertisements that will hopefully be updated with safety information regarding abuse, misuse, 
addiction, physical dependence and tolerance of the drugs.156 This clear guidance, when 
submitted and finalized, could be greatly helpful in clarifying how pharma companies can be 
accountable in advertising the warnings and risks associated with their pharmaceuticals, without 
hurting the success of their promotional campaigns. 
VII. Conclusion 
 Despite persistent attempts to improve and develop the standard of health in the general 
public, pharma companies do not have the best reputations with American consumers. These 
companies are leading sponsors and promoters of innovative drug research and development. 
With the use of DTC ads, pharma companies work to reach a broad base of consumers, looking 
to sell their products for the intended purpose and use advertised. Due to the fact that DTC ads, 
as a form of commercial speech, are likely to remain protected by First Amendment, it is 
 
154 See, United States Department of Health and Human Services, et al., Draft Guidance: Guidance for Industry 
Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products — Content 
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important for these ads to be meticulously regulated. With these ads, arise concerns of 
misrepresentation or misunderstanding of risks and benefits presented. But as is the nature of 
medical and pharmaceutical development, the benefits of advertising these products seem to 
outweigh the risks.  
Most of all, these ads have equalized access to alternative treatment information, by 
empowering and educating consumers of all socioeconomic backgrounds of new drugs. 
Furthermore, it is in the pharma companies’ interests to produce information that is as accurate 
as possible so that the companies can avoid additional expenditure in resources for amended 
advertisements and injured reputations. This article seeks to demonstrate the evolution of 
regulations, case law, and public awareness to show a path towards mutual sharing of 
information and responsibilities for pharmaceutical drug risks and benefits information between 
pharma companies, physicians, and patients.  
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